// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

S Verma - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

BI-10773

High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI

R De Caterina - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Clopidogrel bisulfate

Head-to-head comparison of FFR-CT against coronary CT angiography and myocardial perfusion imaging for the diagnosis of ischaemia

R S Driessen - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

technetium tc 99m tetrofosmin Injection

LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS

G M De Ferrari - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

The prognostic significance of atrial fibrillation in patients with ST-elevation myocardial infarction: a sub-study of the randomized TOTAL trial

E M J Anttonen - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF

J L Halperin - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Pradax

Differential association between the progression of coronary artery calcium and coronary plaque volume progression according to statins

S E Lee - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Impact of diabetes on 5-year clinical outcomes in stable coronary artery disease, across multiple geographical regions and ethnicities. Insights from the CLARIFY registry

K.-H Mak - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Does concordance last over years? From training exercise to practice in the SUCCOUR trial

T Negishi - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial

S Verma - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Liraglutide

Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial

G Chi - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

betrixaban

Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era

Yu Taniguchi - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Epicardial conductance beyond myocardial ischemia: five-year prognostic value of cumulative FFR measurements in patients without ischemia

S Fournier - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Radiation dose reduction in cardiac CT: results from the prospective multicenter registry on radiation dose estimates of cardiac CT angiography in daily practice in 2017

T J Stocker - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events

M Husain - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Liraglutide

Identifying the undiagnosed AF patient through “Know Your Pulseâ€ community pharmacy based events held in ten countries during Arrhythmia Alliance World Heart Rhythm Week 2017

T Lobban - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Prevalence, clinical characteristics and outcomes of procedural complications of percutaneous coronary intervention in non ST-elevation myocardial infarction: insights from the TAO trial

J Abtan - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Heparin

Balance of risk and benefit of spironolactone according to renal function in heart failure patients with preserved ejection fraction

I E Beldhuis - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Spironolactone

Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial

D K McGuire - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

BI-10773

All you need is LE: utility of an abbreviated LACE score in predicting 30-day outcomes among patients hospitalized for Heart Failure (HF)

H G C Van Spall - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved